中文名稱:1-苯基-3-甲基-5-吡唑啉酮(PMP) | 英文名稱:Edaravone |
CAS:89-25-8 | 品牌: 阿拉丁 |
產(chǎn)地: 上海 | 保存條件: -80℃儲存 |
純度規(guī)格: 10mM in DMSO | 產(chǎn)品類別: 藥靶配體 藥靶配體 |
分子式: C10H10N2O | 分子量: 174.2 |
運輸條件: 超低溫冰袋運輸 | 產(chǎn)品規(guī)格: 1ml |
貨號: E408892 | 是否進口: 否 |
中文名:1-苯基-3-甲基-5-吡唑啉酮(PMP)
英文名:Edaravone
英文別名:MCI-186;3-methyl-1-phenyl-1H-pyrazol-5(4H)-one
純度:10mM in DMSO
貨號:E408892
包裝:1ml
Cas號:89-25-8
存儲溫度:-80℃儲存
產(chǎn)品介紹:
Information
Edaravone (MCI-186) is a novel potent free radical scavenger that has been clinically used to reduce the neuronal damage following ischemic stroke.
In?vitro
Edaravone exerts neuroprotective effects by inhibiting endothelial injury and by ameliorating neuronal damage in brain ischemia. Edaravone provides the desirable features of NOS: it increases eNOS (beneficial NOS for rescuing ischemic stroke) and decreases nNOS and iNOS (detrimental NOS). Edaravone, which inhibits oxidation and enhances NO production derived from increased eNOS expression, may improve and conserve cerebral blood flow without peroxynitrite generation during reperfusion.
In?vivo
Edaravone significantly reduces the infarct volume and improves the neurological deficit scores at 24 hours after reperfusion in mice brain. Edaravone markedly suppresses the accumulation of HNE-modified protein and 8-OHdG at the penumbra area during the early period after reperfusion and reduces microglial activation, iNOS expression, and nitrotyrosine formation at the late period. Edaravone attenuates renal function and pathologic findings significantly in rat kidney. Edaravone significantly reduces the generation of free radicals in the tubular cells indicated by dichlorodihydrofluorescein. Edaravone-treated animals shows significantly improved neurological outcome. Edaravone-treatment provides a significant reduction in the number of TUNEL-positive apoptotic cells, a decrease in Bax immunoreactivity and an increase in Bcl-2 expression within the peri-infarct area. Edaravone shows an excellent neuroprotective effect against ischemia/reperfusion brain injury through a Bax/Bcl-2 dependent anti-apoptotic mechanism.
Cell?Data
cell?lines:Bladder epithelial cell line T24, RT-4 transitional cell papilloma bladder cell line, 5637 primary carcinoma bladder cell line, HCT-116, MDAMB231, MCF7, HEK293, A549, SKOV3 and DU145
Concentrations:
Incubation?Time:
Powder?Purity:≥99%
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對應頁面:https://www.aladdin-e.com/zh_cn/E408892.html
成立日期 | 2009-03-16 (17年) | 注冊資本 | 14130.676萬人民幣 |
員工人數(shù) | 500人以上 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 生物化工,化學試劑 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP5年
|
深圳菲斯生物科技有限公司
|
2025-08-19 | |
詢價 |
VIP5年
|
四川省維克奇生物科技有限公司
|
2025-08-19 | |
詢價 |
VIP6年
|
武漢鵬壘生物科技有限公司
|
2025-08-19 | |
¥40 |
VIP6年
|
南京百慕達生物科技有限公司
|
2025-08-19 | |
詢價 |
VIP2年
|
湖北鴻福達生物科技有限公司
|
2025-08-19 | |
¥30 |
VIP4年
|
廣州遠達新材料有限公司
|
2025-08-19 | |
¥1200 |
VIP5年
|
山東穗泰生物科技有限公司
|
2025-08-19 | |
¥100 |
VIP2年
|
中山市迪欣化工有限公司
|
2025-08-19 | |
詢價 |
VIP6年
|
湖北鴻福達生物科技有限公司
|
2025-08-19 | |
¥80.00 |
VIP10年
|
北京索萊寶科技有限公司
|
2025-08-19 |